Preview

Российский кардиологический журнал

Расширенный поиск

ИВАБРАДИН В ЛЕЧЕНИИ БОЛЬНЫХ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ СО СНИЖЕННОЙ ФРАКЦИЕЙ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА: НОВЫЕ ДАННЫЕ ИССЛЕДОВАНИЯ SHIFT

https://doi.org/10.15829/1560-4071-2016-8-80-85

Полный текст:

Аннотация

Частота сердечных сокращений в покое является мощным предиктором неблагоприятного прогноза у больных хронической сердечной недостаточностью. Cелективный ингибитор If -каналов синусового узла — ивабрадин — улучшает клинические исходы больных систолической сердечной недостаточностью с ЧСС в покое ≥70 уд./мин на фоне синусового ритма. В настоящем обзоре представлены данные по эффективности ивабрадина у разных категорий больных, включая пациентов с коморбидными состояниями и тяжелой сердечной недостаточностью.

Об авторах

С. Н. Терещенко
ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России
Россия

д.м.н., профессор, руководитель отдела заболеваний миокарда и сердечной недостаточности,

Москва



И. В. Жиров
ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России
Россия

д.м.н., в.н.с. отдела заболеваний миокарда и сердечной недостаточности,

Москва



Н. В. Романова
ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России
Россия

аспирант отдела заболеваний миокарда и сердечной недостаточности,

Москва



Список литературы

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.

2. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: Trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000; 102: 1126-31.

3. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The rotterdam study. Eur Heart J. 2001; 22: 1318-27.

4. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: A population based study. Heart. 2000; 83: 505-10.

5. Kannel WB, Kannel C, Paffenbarger RSJR, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.

6. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-34.

7. Fox K, Ford I, Steg PG, et al., on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-21.

8. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103: 1428-33.

9. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. EurHeart J 2006; 27: 65-75.

10. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol2008; 101: 865-69.

11. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-74.

12. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008; 31: 95-107.

13. Swedberg K, Komajda M, Böhm M. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11; 376 (9744): 875-85.

14. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebocontrolled trial. Lancet. 2010 Sep 11; 376 (9744): 886-94.

15. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol, 2013 Jan; 102(1): 11-22.

16. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260-6.

17. Abrahamsson P, Dobson J, Granger CB, et al. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. Eur Heart J 2009; 30: 338-45.

18. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-7.

19. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics — 2014 update: A report from the American Heart Association. Circulation 2014; 129: e28-e292.

20. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-19.

21. Chen J, Normand SL, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. J Am Med Assoc 2011; 306: 1669-78.

22. Anker SD, McMurray JJ. Time to move on from ‘time-to-first’: should all events be included in the analysis of clinical trials? Eur Heart J. 2012 Nov; 33 (22): 2764-5.

23. Borer JS, Böhm M, Ford I, et al.; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov; 33(22): 2813-20.

24. McMurray JJ, Adamopoulos S, Anker SD, et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; doi:10.1093/eur heart J/ehs104.

25. Federal clinical recommendations on diagnostics and treatment of chronic and acute heart failure. M: 2013. Available on www.cardioweb.ru. Russian (Федеральные клинические рекомендации по диагностике и лечению хронической и острой сердечной недостаточности. М.: 2013. Доступно на www.cardioweb.ru).

26. Konstam MA, Neaton JD, Dickstein K, et al. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, doubleblind trial. Lancet 2009; 374: 1840-8.

27. Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-84.

28. Komajda M, Böhm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patientswith chronic heart failure. Eur J Heart Fail. 2013 Jan; 15 (1): 79-84.

29. Borer JS, Swedberg K, Komajda M, et al. Beta Blocker Dosage and Use Over Ti me in the Systolic Heart Fai lure Treatment with the If Inhibitor Ivabradine Trial (SH IFT) Study. JACC March 17, 2015 Volume 65, Issue 10S.

30. Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Findings From the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) Study. J Am Coll Cardiol. 2012 May 29; 59 (22): 1938-45.

31. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001-2007.

32. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112: 3738-44.

33. Borer JS, Böhm M, Ford I, et al.; SHIFT Investigators. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol. 2014 Feb 1; 113 (3): 497-503.

34. Böhm M, Robertson M, Ford I, et al. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). Am J Cardiol. 2015 Dec 15; 116(12): 1890-7.

35. Voors AA, van Veldhuisen DJ, Robertson M, et al.; SHIFT investigators. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFTEur J Heart Fail. 2014 Apr; 16(4): 426-34.

36. Tavazzi L, Swedberg K, Komajda M, et al.; SHIFT Investigators. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013 Dec 10; 170 (2): 182-8.

37. Borer J, Swedberg K, Komajda M, et al. Efficacy Profile of Ivabradine in Patients with Heart Failure Plus Angina Pectoris. JACC March 17, 2015 Volume 65, Issue 10S.

38. Reil JC, Robertson M, Ford I, et al. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail. 2013 Sep; 15(9): 1044-52.


Для цитирования:


Терещенко С.Н., Жиров И.В., Романова Н.В. ИВАБРАДИН В ЛЕЧЕНИИ БОЛЬНЫХ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ СО СНИЖЕННОЙ ФРАКЦИЕЙ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА: НОВЫЕ ДАННЫЕ ИССЛЕДОВАНИЯ SHIFT. Российский кардиологический журнал. 2016;(8):80-85. https://doi.org/10.15829/1560-4071-2016-8-80-85

For citation:


Tereshchenko S.N., Zirov I.V., Romanova N.V. IVABRADINE IN PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: NEW DATA FROM THE SHIFT MULTICENTER RANDOMIZED TRIAL. Russian Journal of Cardiology. 2016;(8):80-85. (In Russ.) https://doi.org/10.15829/1560-4071-2016-8-80-85

Просмотров: 330


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)